All In Biotech

Drug Trial Radar · NCT07673627

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Oct 2027

Study completion Apr 2028

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG). The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward2

Conditions

  • AChR-Ab Seropositive Generalized Myasthenia Gravis
  • Myasthenia Gravis (MG)
  • MG - Myasthenia Gravis
  • gMG

Interventions

  • Empasiprubart IVBiological

    Intravenous infusions of empasiprubart

  • Placebo IVOther

    Intravenous infusions of placebo

  • Efgartigimod PH20 SC PFSCombination product

    Subcutaneous administration of efgartigimod PH20 via pre-filled syringe (PFS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and serious adverse events in the DBTPTime frame: Up to 12 weeks

Locations

19 sites in 7 countries. Site status is shown where the registry gives one.

  • Neurology Center of Southern California

    Carlsbad, California · Recruiting

  • Visionary Investigators Network

    Miami, Florida · Recruiting

  • University of South Florida Health

    Tampa, Florida · Recruiting

  • Profound Research LLC at Las Vegas Neurology Center

    Las Vegas, Nevada · Recruiting

  • Dent Neurologic Institute - Amherst

    Amherst, New York · Recruiting

  • Erlanger Health System

    Chattanooga, Tennessee · Recruiting

  • National Neuromuscular Research Institute

    Austin, Texas · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Eginitio Hospital

    Athens, Greece · Recruiting

  • AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • Ospedale Papa Giovanni XXIII

    Bergamo, Italy · Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy · Recruiting

  • Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Sant'Andrea

    Roma, Italy · Recruiting

  • General Hanamaki Hospital

    Hanamaki, Japan · Recruiting

  • National Hospital Organization Sendai Medical Center

    Sendai, Japan · Recruiting

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands · Recruiting

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, Spain · Recruiting

  • Hospital Regional Universitario de Malaga - Hospital General

    Málaga, Malaga, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.